Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

nts who discontinued study therapy in ETV-027, and subsequently restarted treatment in rollover study ETV-901, with a greater than 60 day gap between end of treatment in study ETV-027 and start of treatment in study ETV-901.

    -- ETV-027 compared 0.5 mg of BARACLUDE vs. 100 mg of lamivudine in
nucleoside-naive chronic HBeAg-negative chronic hepatitis B patients.
-- Rollover study ETV-901 was established as an open-label, follow-up
protocol for patients in phase II and III studies of BARACLUDE.
-- Due to ongoing blinding of study ETV-027, most patients retreated in
ETV-901 initially received a combination of 1 mg of BARACLUDE plus 100
mg of lamivudine, and were subsequently switched to 1 mg of BARACLUDE
monotherapy.

The analysis cohort was defined regardless of treatment response at the end of dosing in study ETV-027, and independent of virologic or ALT measurements at the start of dosing in study ETV-901. During off-treatment follow-up, the majority of patients had recurrent levels of hepatitis B virus in the blood (viremia) and increases in ALT.

    Data Results
At the end of dosing for study ETV-027:
-- 94 percent (n=93/99) of the re-treatment cohort had undetectable viral
load
-- 78 percent (n=77/99) had ALT normalization
At entry into ETV-901:
-- Four percent (n=4/99) of patients had undetectable viral load
-- Eight percent (n=8/97) of patients had ALT normalization
Following re-treatment in study ETV-901:
-- 93 percent (n=82/88) of patients had undetectable viral load (HBV DNA
<300 copies/mL) by week 48 of re-treatment with BARACLUDE
-- 83 percent (n=79/95) of patients had ALT normalization (ALT less than
or equal to 1 times the upper limit of normal) by week 48 of re-
treatment BARACLUDE
Adverse events in study ETV-027/901 re-treatment cohort:
-- 67 percent (n=66/99) of patients experienced an adverse event. The most
common adverse events occurring in greater than ten percent of patients
were abdominal pain, fa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:8/4/2015)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Chief Executive Officer, Doug Godshall , is scheduled ... Conference at 8:30 a.m. EDT on Thursday, August 13, ... at the InterContinental Boston. A live webcast ...
(Date:8/4/2015)... , Aug. 04, 2015 ... has announced the addition of the "MRI ... Comfort and Operational Efficiency, with Growth Driven by ... "MRI Systems Market to 2020 - Focus ... Driven by Developing Economies" discusses the market, competitive ...
(Date:8/4/2015)...  Dr. Keesha Ewers of The ... of flibanserin, or what is being touted as ... decreased female sexual desire back several decades. Diminished ... addressing libido as a singular symptom with a ... Photo - http://photos.prnewswire.com/prnh/20150804/254705 ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... Open-Label Study Presented at Federation of,Clinical Immunology ... June 11, 2007 /PRNewswire-FirstCall/ --,Orchestra Therapeutics, Inc. ... from its completed Phase II open-label study ... peptide,vaccine for the treatment of relapsing-remitting multiple ...
... -- NovaCardia, Inc.,today presented preliminary results from a ... receptor antagonist in development for the,treatment of patients ... strong trend toward efficacy for the 30 milligram,dose. ... of,improvement in dyspnea, or shortness of breath, which ...
Cached Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4
(Date:8/4/2015)... ... 04, 2015 , ... World Patent Marketing, a vertically integrated ... fitness invention that eliminates the need to have a partner or trainer when ... is worth $30 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:8/4/2015)... Birmingham, OH (PRWEB) , ... August 04, 2015 ... ... announce that it has joined the American Association of Tissue Banks (AATB) as ... AATB and its mission “to honor donors, and to save and improve lives ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... technology platform that uses Cloud innovation to consolidate oncology patient assistance programs. Through ... a single point of access. assistPoint is an enterprise level, cloud-based application and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Atlantic Health System, one of the largest health ... among the top five in their list of the 20 Best Workplaces in Health ... Chilton Medical Centers, Goryeb Children’s Hospital and Atlantic Rehabilitation, is the highest-ranking company from ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... on sexual and reproductive health and rights in Indonesia for a select group ... a number of sites in Indonesia and attend the International Conference on Family ...
Breaking Medicine News(10 mins):Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:assistPoint.com Web Site Launched 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2
... reward pathways as booze , TUESDAY, June 22 (HealthDay News) ... option for alcoholism, a new animal study suggests. , Alcoholism ... and eat), which leads to disrupted sleep patterns. As a ... attempt to fall asleep easier. But this often leads to ...
... 2 chances, study finds , TUESDAY, June 22 (HealthDay News) ... the waist, significantly increases your risk of type 2 diabetes, ... stable after age 50, people who gained the most weight ... of developing type 2 diabetes, according to the study in ...
... response to the H1N1 flu, most employees at U.S. businesses ... such as encouraging sick employees to stay home, according to ... Opinion Research Program at Harvard School of Public Health (HSPH). ... took other actions such as creating back-up systems for employees ...
... ... in the US to utilize Mayo Clinic Embody Health Program. , ... (PRWEB) June 22, 2010 -- St Gregory Centers, Inc. ... provide wellness programming for St Gregory clients and employees. The Mayo Clinic program will ...
... care of sick or disabled loved ones is widely recognized ... life, a new study led by University at Buffalo psychologist ... loved ones may promote the well being of helpers. "Does ... journal Psychology and Aging (2010, Vol. 25., No. ...
... risk of obesity, but a new study shows that a ... their parents helps the children reduce body fat and improve ... Society,s 92nd Annual Meeting in San Diego. Such interventions ... the study,s lead author Jardena Puder, MD, said. A senior ...
Cached Medicine News:Health News:Exercise May Combat Alcohol Cravings, Animal Study Suggests 2Health News:Gaining Weight Later in Life Ups Diabetes Risk 2Health News:Gaining Weight Later in Life Ups Diabetes Risk 3Health News:Employers took many measures to protect employees and avoid business impact of H1N1 flu outbreak 2Health News:Employers took many measures to protect employees and avoid business impact of H1N1 flu outbreak 3Health News:Employers took many measures to protect employees and avoid business impact of H1N1 flu outbreak 4Health News:St. Gregory Centers, Inc. Announces Integrating Mayo Clinic Health Wellness Program 2Health News:Study finds that caring for an elderly, sick spouse sometimes has positive elements 2Health News:Lifestyle intervention reduces preschoolers' body fat, improves fitness 2
... 12 mm linear cutting stapler for resection, ... ,The stapler places two triple, staggered rows ... divides the tissue in between. The instrument ... single surgical procedure: it can be reloaded ...
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
Single Use Loading Units (SULU's) with Titanium Staples for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
ENDO GIA ROTICULATOR™ Single Use Loading Units with Titanium Staples for use with the ENDO GIA™ Universal and GIA™ Universal Instrument (030403) Single Use Instrument (030449)....
Medicine Products: